Pharmacological blockade of CDC42 abrogated the compelling difference in migration and invasion ability between MDA-MB-231 cells with TTC17-knockdown shRNA or scramble control, thereby confirming that the TTC17-mediated RAP1/CDC42 pathway was responsible for tumor progression (Fig. 4h, i). The gene discussed is TTC17; the disease is neoplasm.